KATHARINE MCLEESE: Open Payments
NPI 1821107947 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$699 in 46 payments from 17 companies in 2025. Trend: 2023 $694 · 2024 $723 · 2025 $699
Food & beverage: $699
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 13 | $150 |
| Sumitomo Pharma America, Inc. | 3 | $64 |
| Astellas Pharma US Inc | 3 | $59 |
| ABBVIE INC. | 3 | $54 |
| Novo Nordisk Inc | 3 | $52 |
| AstraZeneca Pharmaceuticals LP | 3 | $52 |
| PFIZER INC. | 3 | $47 |
| Merck Sharp & Dohme LLC | 3 | $46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $37 |
| Amgen Inc. | 2 | $27 |
Products named: MOUNJARO, GEMTESA, Veozah, GARDASIL 9, EVENITY, JARDIANCE, LINZESS, Rybelsus.
Industry payments across NE — which companies pay providers there.
